Pacira BioSciences Inc.

PCRX

Held by 4 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

4 funds opened new positions. Next phase3 readout (ZILRETTA): Dec 2026. Short interest: 23.1% of float.

Catalysts

Phase 2Q1 2006SKY0402Inguinal HerniaNCT01203644

Primary: Time to First Use of Supplemental Pain Medication (Through 96 hours postdose)Enrollment:76/76RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ1 2006SKY0402Postoperative PainNCT01206595

Primary: Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain (Through 96 hours postdose)Enrollment:58/58RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ4 2007SKY0402Postoperative PainNCT00529126

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours (0 to 72 hours)Enrollment:100/100Sites: 7RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ3 2008SKY0402 + bupivacaine HClPostoperative PainNCT01206608

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) and With Activity (NRS-A) Pain Intensity Scores (Through 96 hours postdose)Enrollment:40/40Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2009Bupivacaine HClPostoperative PainNCT00745290

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores (through 72 hours post surgery)Enrollment:245/245Sites: 19RANDOMIZED, DOUBLE, SUPPORTIVE_CARE

Phase 2NegativeQ1 2009Low Dose SKY0402Postoperative PainNCT00807209

Primary: Amount of Rescue PCA Fentanyl Administered for Breakthrough Pain During the First 72 Hours. (72 hours)Enrollment:3/3Sites: 5RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2009SKY0402PainNCT00813111

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores (through 72 hours)Enrollment:136/136Sites: 15RANDOMIZED, DOUBLE, SUPPORTIVE_CARE

Phase 2PositiveQ3 2009Bupivacaine HClPostoperative PainNCT00485693

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores Through Postoperative Day 4 (0 to 96 hours)Enrollment:138/138Sites: 9RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2009SKY0402Bunion, Hallux ValgusNCT00890682

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores (0-24 hours)Enrollment:193/193Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2009SKY0402HemorrhoidNCT00890721

Primary: The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo. (72 hours)Enrollment:189/189Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2011Facial WrinklesNCT01167140

Primary: Number of Participants With Effectiveness and Safety Success (Up to 4 months)Enrollment:42/42Sites: 1NA, TREATMENT

Phase 3Q1 2012Facial Wrinkles, Skin AgingNCT01447342

Primary: Effectiveness success (Up to 4 months)Enrollment:54/54Sites: 3NA, TREATMENT

Phase 2Q1 2012FX005Osteoarthritis, KneeNCT01291914

Primary: Change from baseline in the WOMAC A score (pain subscale) (at 4 weeks post treatment)Enrollment:140/140Sites: 13RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2012FX006 10 mgOsteoarthritis of the KneeNCT01487200

Primary: Change From Baseline in 24-hour Weighted Mean Serum Cortisol (Days 1-2, Days 14-15 (Week 2) and Days 42-43 (Week 6))Enrollment:24/24Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2013FX006Osteoarthritis of the KneeNCT01487161

Primary: Change From Baseline to Week 8 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg (8 weeks)Enrollment:229/229Sites: 21RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2013EXPAREL 266 mgPosterolateral Thoracotomy, Postoperative PainNCT01802411

Primary: Area Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours (0-72 hours postsurgery)Enrollment:191/191Sites: 21RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2013PlaceboPostoperative PainNCT01683071

Primary: Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours (0-72 hours)Enrollment:297/297Sites: 30RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2014FX006 10 mgOsteoarthritis of the KneeNCT02003365

Primary: Concentration of Triamcinolone Acetonide in Synovial Fluid (12 to 20 weeks)Enrollment:50/50Sites: 3NON_RANDOMIZED, TREATMENT

Phase 3Q4 2014Facial Wrinkles, Skin AgingNCT01379365

Primary: Wrinkle Severity and incidence of device-related serious adverse events (Up to 4 months)Enrollment:88/88Sites: 1NA, TREATMENT

Phase 2PositiveQ4 2015FX006 32 mgOsteoarthritis of the KneeNCT02116972

Primary: Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores for 32 mg FX006 Versus Placebo (Baseline and Week 12)Enrollment:310/310Sites: 44RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2016FX006Osteoarthritis of the KneeNCT02357459

Primary: Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain (ADP) Intensity Scores for 32 mg FX006 Versus Placebo (Baseline and 12 Weeks)Enrollment:486/486Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2016Bupivacaine liposomeDental PainNCT02517905

Primary: Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours (0-48 hours)Enrollment:166/166Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2016FX006 32 mgPost-traumatic Osteoarthritis of the KneeNCT02468583

Primary: Average Change From Baseline in the Weekly Mean of the Average Daily (24-hour) Pain Intensity Scores Over Weeks 5 to 10 (5-10 Weeks)Enrollment:6/6Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ4 2016FX006 32 mgOsteoarthritis of the Knee, Type 2 Diabetes MellitusNCT02762370

Primary: Change From Baseline for Average Blood Glucose (mg/dL) (Baseline and 72 Hours post intra-articular (IA) injection)Enrollment:33/33Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2017bupivacaine liposome injectable suspensionPainNCT02713230

Primary: Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores (0-48 hours)Enrollment:156/156Sites: 20RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ4 2017DepoTXATotal Knee ArthroplastyNCT02922582

Primary: Area Under the Plasma Concentration-versus-time Curve From Time 0 Extrapolated to Infinity After Drug Administration (Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.)Enrollment:16/16Sites: 5RANDOMIZED, SINGLE, TREATMENT

Phase 2PositiveQ1 2018FX006 32 mgBilateral Knee OsteoarthritisNCT03378076

Primary: Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma (43 days)Enrollment:24/24Sites: 3RANDOMIZED, TREATMENT

Phase 3Q3 2018FX006 32 mgOsteoarthritis of the KneeNCT03046446

Primary: Total Number of Treatment Emergent Adverse Events (TEAEs) in Patients With Symptomatic Osteoarthritis (OA) of the Knee Who Received Two Doses of 32 mg FX006 (Up to 52 Weeks)Enrollment:208/208Sites: 17NA, TREATMENT

Phase 2Q4 2018FX006 32 mgOsteoarthritis of the Shoulder, Osteoarthritis of the HipNCT03382262

Primary: Concentration of Triamcinolone Acetonide (TA) in Blood Plasma (12 Weeks)Enrollment:55/55Sites: 6RANDOMIZED, TREATMENT

Phase 3NegativeQ3 2019FX006Osteoarthritis, HipNCT03793010

Primary: Change in WOMAC A (Pain) Score at Week 12 (Baseline and Week 12)Enrollment:70/70Sites: 32RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2019ExparelPostoperative Pain ManagementNCT03682302

Primary: Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Infinity (15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery))Enrollment:98/98Sites: 17RANDOMIZED, TREATMENT

Phase 2Q4 2019FX006 32 mgOsteoarthritis, HipNCT04065074

Primary: Number of Patients With Successful Study Drug Administrations (Day 1)Enrollment:16/16Sites: 5NA, OTHER

Phase 3PositiveQ4 2019FX006 32 mgOsteoarthritis, KneeNCT03529942

Primary: Mean Standardized Change in Synovial Volume (SV) at 6 Weeks (Baseline to Week 6)Enrollment:129/129Sites: 10NA, TREATMENT

Phase 2NegativeQ2 2020FX006Osteoarthritis of the Shoulder, Adhesive CapsulitisNCT04160091

Primary: Area Under the Curve of the Change From Baseline in the Weekly Mean of the Daily Shoulder Pain With Movement (Baseline to 8 weeks)Enrollment:19/19Sites: 27RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2020EXPAREL 13.3Mg/mL Suspension for InjectionBunion, Metatarsophalangeal Fusion, Midfoot FusionNCT03954639

Primary: Magnitude of analgesic effect (0 hours to 96 hours)0RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2021ExparelLower Extremity Surgery, Bunion, Metatarsophalangeal FushionNCT04518462

Primary: Magnitude of the Analgesic Effect (NRS Pain Intensity) (AUC) (Post surgery - 96 hours)Enrollment:121/121Sites: 5RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2022bupivacaine liposome injectable suspensionKnee Osteoarthritis, Pain ManagementNCT05139030

Phase 3Q3 2022Bupivacaine liposome injectable suspension 266 mgBunionectomy, Hallux ValgusNCT05157841

Phase 2NegativeQ4 2025ZilrettaOsteoarthritis of HipNCT06977568

Phase 3Q4 2026ZILRETTAGlenohumeral OsteoarthritisNCT06269705

Phase 2Q3 2032Enekinragene Inzadenovec (PCRX-201)Osteoarthritis (OA) of the KneeNCT06884865

Pacira BioSciences Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research